8-K: Paysign Soars on 40% Revenue Growth, Strong 2025 Performance

Paysign, Inc. reported record full-year 2025 financial results, driven by a 40.5% revenue increase and significant margin expansion, primarily from its patient affordability solutions.

Summary

• Full-year 2025 total revenues reached $82.0 million, marking a 40.5% increase from 2024.
• Pharma industry revenue surged by 167.8% to $33.89 million, driven by the addition of 55 net patient affordability programs, totaling 131 active programs.
• Plasma revenue increased by 4.0% to $45.62 million, with the net plasma center count growing by 115 to 595 centers by year-end.
• Patient affordability claim volume increased over 79% during 2025 compared to the prior year.
• Full-year 2025 net income nearly doubled to $7.55 million, or $0.13 per diluted share, up 97.9% from $3.82 million, or $0.07 per diluted share, in 2024.
• Adjusted EBITDA for full-year 2025 was $19.94 million, an increase of 107.3% from $9.62 million a year ago.
• The company exited 2025 with a strong balance sheet, including $21.07 million of unrestricted cash and zero debt.
• 100,000 shares of common stock were repurchased for $376 thousand during the year.
• Restricted cash balances increased 29.0% to $143.92 million.
• The acquisition of Gamma Innovation LLC closed on March 19, 2025, with its Blood Establishment Computer System (BECS) currently under U.S. Food and Drug Administration review.
• Fourth quarter 2025 total revenues were $22.76 million, up 45.8% from the fourth quarter of 2024.
• Fourth quarter 2025 net income was $1.36 million, or $0.02 per diluted share, a slight decrease of 0.8% compared to $1.37 million, or $0.02 per diluted share, in Q4 2024.
• Fourth quarter 2025 Adjusted EBITDA increased 89.6% to $5.43 million from $2.86 million in Q4 2024.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive report, marked by exceptional revenue and profit growth, significant margin expansion, a strong balance sheet, and an optimistic outlook for 2026, driven by its high-margin patient affordability segment.

Positives

• Achieved record topand bottom-line results for the full year 2025.
• Total revenues increased by an impressive 40.5% to $82.0 million for the full year 2025.
• Pharma industry revenue saw exceptional growth of 167.8% to $33.89 million, driven by successful patient affordability programs.
• Net income nearly doubled, increasing 97.9% to $7.55 million for the full year.
• Adjusted EBITDA more than doubled, growing 107.3% to $19.94 million for the full year.
• Gross profit margin expanded to 59.4% in 2025 from 55.1% in 2024, indicating improved profitability.
• Operating margin significantly improved to 9.0% in 2025 from 1.7% in 2024.
• Maintained a strong balance sheet with $21.07 million in unrestricted cash and zero debt at year-end.
• Repurchased 100,000 shares of common stock, demonstrating confidence in the company's value.
• Successfully closed the Gamma Innovation LLC acquisition, expanding capabilities in the life sciences sector.
• Provided a strong 2026 outlook, projecting revenue growth of 30.0% to 35.0% and net income estimated to nearly double.

Negatives

• Average revenue per plasma center per month decreased to $7,067 in Q4 2025 from $7,510 in Q4 2024, attributed to elevated plasma inventory levels and reduced donations per center.
• Fourth quarter 2025 net income experienced a slight decrease of 0.8% to $1.36 million compared to $1.37 million in Q4 2024, despite strong revenue growth.
• The full-year 2025 effective tax rate increased significantly to 24.7% from 7.8% in 2024.
• The fourth quarter 2025 effective tax rate was 45.4% compared to an income tax benefit of (11.1%) in Q4 2024.
• Other income decreased by $446 thousand, primarily due to implied interest expense related to the Gamma acquisition and lower interest rates.
• Cost of revenues increased 27.2% due to higher call center support expenses, wage inflation, a tight labor market, increased benefit costs, sales and commission expenses, network fees, and third-party variable costs.

Risks

• Inability to continue the current growth rate in future periods.
• A downturn in the economy could reduce the customer base and demand for products and services, which could have an adverse effect on business, financial condition, profitability, and cash flows.
• Operating in a highly regulated environment.
• Failure by Paysign or business partners to comply with applicable laws and regulations.
• Changes in laws, regulations, credit card association rules, or other industry standards affecting the business.
• A data security breach could expose Paysign to liability and protracted and costly litigation.
• Other risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2025.

Future Outlook

Paysign anticipates 2026 revenue to be between $106.5 million and $110.5 million, representing 30.0% to 35.0% year-over-year growth, with both plasma and pharma segments contributing equally. Gross profit margins are expected to range from 60.0% to 62.0%. Net income is projected to nearly double over 2025, reaching $13.0 million to $16.0 million, or $0.21 to $0.26 per diluted share. Adjusted EBITDA is forecast to be in the range of $30.0 million to $33.0 million, or $0.49 to $0.53 per diluted share. For the first quarter of 2026, revenue is expected to be $27.0 million to $27.5 million, with operating margins between 20.0% to 22.0%.

Management Comments

• "2025 was a standout year for Paysign, delivering record topand bottom-line results."
• "Our differentiated solution for patient affordability enabled growth of more than 167%."
• "Patient affordability has become a primary driver of both growth and profitability."
• "Demand for our differentiated solutions is strong and growing, reflecting the value of our technology, service model and real-time claims capabilities."
• "As patient affordability continues to represent a larger portion of our business, the benefits of a more favorable revenue mix, with higher margins and increased operating leverage, are translating to the bottom line."
• "We believe we remain in the early stages of this opportunity and are well positioned to continue expanding our presence in the life sciences ecosystem."
• "Paysign enters 2026 in the strongest position in its history."
• "With strong revenue growth and improving operating leverage, we are positioned for continued success."

Industry Context

StockSavvy.ai notes that Paysign's strong performance, particularly in patient affordability solutions, aligns with the growing demand for financial assistance in the life sciences sector. The increasing complexity of healthcare costs and insurance structures drives the need for effective copay mitigation and patient access programs, positioning Paysign favorably within this expanding niche. The acquisition of Gamma Innovation LLC and its BECS under FDA review also indicates a strategic move to enhance offerings in the blood and plasma industry, a critical component of the broader healthcare ecosystem.

Comparison to Industry Standards

• The 167.8% increase in pharma revenue driven by patient affordability programs significantly outperforms typical growth rates in mature payment processing or healthcare IT sectors, indicating strong market penetration and demand for Paysign's specialized solutions.
• The expansion of gross profit margin to 59.4% and operating margin to 9.0% suggests superior operational efficiency and pricing power compared to many general payment processors, which often operate on thinner margins due to higher competition and commoditization.
• The zero debt position and substantial unrestricted cash balance of $21.07 million provide a strong financial foundation, contrasting with many growth companies that rely heavily on debt or equity financing for expansion.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, significant growth in revenue and profitability, share repurchase program, and optimistic future outlook, potentially leading to increased share value.
• Patients: Improved access to prescribed therapies through patient affordability solutions, mitigating copay costs.
• Plasma Donors: Continued compensation programs, though average revenue per center declined slightly due to elevated inventory.
• Pharmaceutical Manufacturers/Program Sponsors: Positive impact through effective patient affordability solutions, demonstrating positive ROI and improved patient access.
• Employees: Increased call center support expenses and investments in people and technology suggest potential for job growth and competitive compensation, though wage inflation pressures were noted.

Next Steps

• Continued investment in people and technology throughout 2026.
• Gamma Innovation LLC's Blood Establishment Computer System (BECS) is currently under U.S. Food and Drug Administration review.

Key Dates

Recommendation

The company delivered exceptional full-year 2025 results with robust revenue growth, significant margin expansion, and a near doubling of net income and Adjusted EBITDA. The patient affordability segment is a high-growth, high-margin driver, and the company maintains a strong balance sheet with zero debt. The 2026 outlook projects continued strong growth and profitability, indicating sustained positive momentum. These factors collectively suggest a strong investment opportunity.

Keywords

Paysign, PAYS, financial results, earnings, patient affordability, plasma compensation, fintech, healthcare payments, life sciences, Q4 2025, full-year 2025, revenue growth, Adjusted EBITDA, net income, corporate governance, SEC filing, Form 8-K